New ADHD drug studied in preschoolers: hope or hype?
NCT ID NCT05721235
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at the safety and tolerability of the drug Azstarys in 123 children aged 4 to 5 with ADHD over 12 months. Researchers monitored sleep, weight, and height changes, as well as how well the drug controlled ADHD symptoms. The goal was to see if this medication could be a safe option for managing ADHD in this young age group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Azstarys (serdexmethylphenidate and dexmethylphenidate)
What this could lead to
If successful, this could provide a treatment option for managing ADHD symptoms in younger children, potentially improving focus and behavior.
What could go wrong
This is a small, early-phase study without a placebo group, so results may not confirm effectiveness. Side effects like sleep problems or changes in weight and height are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATTENTION-DEFICIT / HYPERACTIVITY DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AIM Trials
Plano, Texas, 75093, United States
-
Accel Research Sites - Lakeland
Lakeland, Florida, 33803, United States
-
Accel Research Sites - Maitland
Maitland, Florida, 32751, United States
-
Advanced Research Center (ARC)
Anaheim, California, 92805, United States
-
Alivation Research, LLC
Lincoln, Nebraska, 68526, United States
-
Boeson Research
Missoula, Montana, 59804, United States
-
CNS Healthcare - Orlando
Orlando, Florida, 32801, United States
-
CenExel iResearch, LLC
Savannah, Georgia, 31405, United States
-
Center For Psychiatry and Behavioral Medicine Inc
Las Vegas, Nevada, 89128, United States
-
Clinical Neuroscience Solution, Inc
Memphis, Tennessee, 38119, United States
-
Clinical Neuroscience Solutions - Orlando
Jacksonville, Florida, 32256, United States
-
DelRicht Research - Touro Medical Center
New Orleans, Louisiana, 70115, United States
-
Flourish Research
San Antonio, Texas, 78229, United States
-
Houston Clinical Trials
Bellaire, Texas, 77401, United States
-
IMMUNOe International Research Center
Centennial, Colorado, 80112, United States
-
Preferred Research Partners (PRP)
Little Rock, Arkansas, 72211, United States
-
Sky Clinical Research Network Group P.C.
Union City, Georgia, 30291, United States
-
South Florida Research Phase I-IV INC
Miami Springs, Florida, 33166, United States
-
St Charles Psychiatric Associates & Midwest Research Group
Saint Charles, Missouri, 63304, United States
-
iResearch Atlanta
Decatur, Georgia, 30030, United States